CDMO and CRO selection should be evaluated as a regulatory and quality decision first, and a procurement decision second, using inspection history and oversight model design as the evaluative frame.
White Paper
Your CDMO Is Part of Your Regulatory Strategy
Related Resources
All Resources
case-study
Partnership with a Canadian Pharma Organization resulted in savings in effort and material cost for time-critical clinical program
Read More
case-study
Partnership helped to reduce time to market by ensuring for U.S. based virtual Biopharmaceutical company
Read More
case-study
Process improvements and in-person monitoring help U.S. pharmaceutical company achieve on time for Phase III clinical trials
Read More
post
Exploring Risk-Based Approaches to Raw Material Testing in Pharmaceutical Manufacturing
Read More
Let's move from science to success.
Let’s Talk